Troleandomycin is a macrolide antibiotic used for the treatment of bacterial infections of the upper and lower respiratory tract such as tonsilitis, bronchitis, sinusitis and pneumonia. Troleandomycin targets the protein synthesis machinery in the bacterial cytoplasm to inhibit protein synthesis and prevent bacterial growth. Troleandomycin enters through the bacterial cell membrane through multidrug resistant protein 1 and binds to the bacterial ribosome. The bacterial ribosome consists of two subunits: the 50s and the 30s subunit. Troleandomycin binds to the 50s subunit and prevents translocation of the tRNA along the A, P and E sites of the ribosome. Translocation of amino acids from the acceptor site (A site) to the donor site (P site) is prevented and as a result, protein synthesis is halted. The bacterial cells are unable to generate proteins necessary for growth and duplication, therefore, growth of the bacteria is inhibited. Side effects from taking troleandomycin may include abdominal cramping and discomfort, nausea and vomiting, diarrhea, dizziness, fatigue, headache, vaginal yeast infection and allergic reactions including urticaria, skin rashes and anaphylaxis.

Troleandomycin Pathway (New) References